King Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From King Pharmaceuticals, Inc.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
There are a raft of investigational products looking to move into the rapidly growing hidradenitis suppurativa market and AbbVie is hoping to grab a decent share with two assets, the anti-interleukin-1 alpha and beta monoclonal antibody lutikizumab and its anti-inflammatory blockbuster Rinvoq.
Eisai and Lilly were the biggest winners at the 19th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.
Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.
- Medical Devices
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Alpharma Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.